Bioxyne Secures $1.7M Scottish Government Funding to Establish UK Medicinal Cannabis Manufacturing Facility
Key Insights
Bioxyne (search)'s subsidiary Breathe Life Sciences (search) UK received approximately $1.7 million in funding from South of Scotland Enterprise (search) to establish a medicinal cannabis (search) manufacturing and distribution facility in the Scottish Borders region.
The UK represents the second-largest medicinal cannabis (search) market in Europe after Germany, with patients spending an estimated average of $6,572 annually on medicinal cannabis in 2024.
The company recently fulfilled its first orders for Australian-made GMP MDMA capsules for PTSD (search) treatment, positioning itself at the forefront of emerging mental health treatments.
Australian pharmaceutical company Bioxyne (search) has secured approximately $1.7 million in funding from South of Scotland Enterprise (search) (SOSE) to establish a medicinal cannabis (search) manufacturing and distribution facility in the UK through its subsidiary Breathe Life Sciences (search) UK. The funding package comprises a five-year loan facility worth approximately $1 million and a grant award of approximately $700,000.
The strategic expansion targets the UK's rapidly growing medicinal cannabis (search) market, which currently ranks as the second-largest in Europe after Germany. UK patients demonstrated an estimated average annual spend of around $6,572 per patient on medicinal cannabis in 2024, significantly higher than Germany's approximately $1,342 per patient.
Market Opportunity and Infrastructure Gap
Bioxyne (search) CEO Sam Watson highlighted the significant market opportunity presented by the UK's supply-demand imbalance. "The UK market is seeing tremendous year-on-year growth but its existing manufacturing infrastructure is not sufficient to keep up with local demand, which presents an opportunity for our subsidiary to enter and grow with the market," Watson said.
The company has secured a site in the Scottish Borders region equivalent in size to its Queensland facility, positioning itself to become a significant provider of manufacturing and distribution services to the UK medicinal cannabis (search) market. Breathe Life Sciences (search) UK plans to complete the facility fit-out and submit applications to the Medicines and Healthcare products Regulatory Agency for required licenses by 2026.
Expanding Therapeutic Portfolio
Founded in 2018, Breathe Life Sciences (search) has evolved into a multinational business focused on alternative therapeutics and investigational medicines. The company operates as a manufacturer, wholesaler, and importer-exporter of controlled substances including medicinal cannabis (search), psilocybin, and MDMA, with licensed manufacturing and distribution centers across Australia, Japan, the UK, and Czechia.
The company recently achieved a significant milestone by fulfilling two standing purchase orders for BLSMD40 (search) MDMA capsules for post-traumatic stress disorder (search) (PTSD (search)) treatment in Australia. As Australia's first TGA GMP-licensed pharmaceutical manufacturer of psychedelic and psychoactive medicines, Breathe Life Sciences (search) supplied capsules meeting Australian and international pharmaceutical standards to clinical trials in Victoria and authorized prescribers in Queensland.
PTSD Treatment Market Potential
The MDMA capsule orders address a substantial unmet medical need, with approximately 12% of Australians experiencing PTSD (search) during their lifetime. Initial purchase volumes will cover more than 400 patient doses, with BLSMD40 (search) being supplied via Australia's Authorized Prescriber pathway for MDMA-assisted therapy targeting treatment-resistant PTSD.
Watson emphasized the significance of local manufacturing capabilities: "By leveraging Bioxyne (search)'s manufacturing capabilities, the mental health sector can now source high-quality Australian-made medication for patients suffering from PTSD (search)."
Strategic Partnerships and Revenue Projections
Bioxyne (search) has secured an exclusive agreement with Curaleaf International (search) for the import, manufacture, and supply of the Curaleaf Que discreet medical inhalation device for use with medical cannabis liquid inhalants. This collaboration is expected to generate recurring revenue streams supporting the company's 2026 financial year guidance of between $65 million and $75 million, with forecast EBITDA of up to $13.5 million.
Regional Economic Impact
SOSE Chief Executive Jane Morrison-Ross expressed enthusiasm for the investment, noting that the agency has witnessed inward investment inquiries increase by over 450%, with a surge in innovative life sciences and energy companies. "The arrival of Breathe Life Sciences (search) is further confirmation that our region is the place to do innovative business," Morrison-Ross said.
The global psychedelic drugs market is forecast to grow to approximately $14 billion by 2032, reflecting rising acceptance of psychedelic-assisted therapies and positioning Bioxyne (search)'s diversified controlled substances portfolio for significant growth across multiple therapeutic areas.